Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
19
|
| pubmed:dateCreated |
1997-1-23
|
| pubmed:abstractText |
Although rare (10% of thyroid cancers), medullary thyroid cancer is remarkable by the presence of a specific biological marker; elevation of blood calcitonin. It allows its preoperative diagnosis and this extensive surgery which is the only efficient treatment. The possibility of hereditary form (30%) must always be kept in mind; they can now be detected by genetic screening since specific mutations on Ret gene have been recently discovered. Follow up and early treatment of at risk subjects in a family is therefore possible and permits definitive surgical cure.
|
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
F
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0035-2640
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2303-8
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
1996
|
| pubmed:articleTitle |
[Medullary cancer of the thyroid].
|
| pubmed:affiliation |
Service d'endocrinologie, Hôpital Avicenne, Bobigny.
|
| pubmed:publicationType |
Journal Article,
English Abstract,
Review
|